Aller au contenu principal
Accès ouvert déclaré 2025 article

Model‐Informed Drug Development Supports Full Approval of Ibuprofen Injection in Chinese Pediatric Patients With Fever or Pain

1Citations signalées — pas une note de qualité
8Institutions déclarées
2Pays d’affiliation déclarés

Résumé fourni par la source

Ibuprofen is a commonly used nonsteroidal anti-inflammatory drug, and its injectable form has specific clinical applications. However, ibuprofen injection has not been approved for use in Chinese children. This study aimed to support its approval in this population using a model-informed drug development (MIDD) approach. Ibuprofen injection (Fenliping®) received approval for Chinese pediatric indications in 2019, with a clinical trial waiver based on pediatric extrapolation using modeling and simulation. A physiologically based pharmacokinetic (PBPK) model was used to assess ethnic differences and determine the optimal dose for Chinese children. A single-arm, open-label trial was conducted in 40 pediatric patients aged 0.5-6 years to confirm the appropriateness of the 10 mg/kg dose. Body temperature, pain scores, and adverse events were collected to evaluate efficacy, safety, tolerability, and were used as clinical endpoints for exposure-response analysis. Sparse sampling was applied for pharmacokinetic analysis. A population pharmacokinetic (PopPK) model was developed using clinical data and used to refine the PBPK model and compare pharmacokinetics between Chinese and Caucasian children. Exposure-response analysis evaluated the relationship between exposure and clinical outcomes. The PBPK model showed minimal ethnic impact on pharmacokinetics, supporting a 10 mg/kg dose. In febrile patients, 89.5% achieved temperature < 38.5°C within 4 hours. Pain scores decreased below threshold. One mild drug-related adverse event occurred. PK parameters were comparable across ethnicities, and no exposure-response relationship was observed. The MIDD approach supported full approval of ibuprofen injection in Chinese children. A 10 mg/kg dose was effective, safe, and well-tolerated.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
Model‐Informed Drug Development Supports Full Approval of Ibuprofen Injection in Chinese Pediatric Patients With Fever or Pain
Date Crossref
25/11/2025
Éditeur
Wiley
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude et ne compte pas comme une seconde source scientifique indépendante.

Institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Sujets associés

Pediatric Pain Management TechniquesInflammatory mediators and NSAID effectsAntibiotics Pharmacokinetics and Efficacy

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.